Evaluation of Fractional Exhaled Nitric Oxide During SARS-CoV-2 Infection

Betancor, Diana; Valverde-Mongue, M; Gómez-López, Alicia; Barroso, Bruna Silveira; Ruete, L; Olaguíbel, J M; Sastre, Joaquı́n

doi:10.18176/jiaci.0762

Cited by 9 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors also demonstrated that FeNO ≤11.8 ppb is predictive of severe outcomes. This finding contrasts with ours [2], which indicate no significant differences in FeNO values according to disease severity. Three studies with hospitalized post-COVID-19 populations performed 3 to 6 months after the initial infection report different results [7][8][9].…”

Section: To the Editorcontrasting

confidence: 99%

“…Inclusion criteria vary widely not only for affected patients (eg, symptomatic respiratory disease [2], mild/severe COVID-19 [3], and critical illness [4]), but also for healthy control groups [5,6]. Moreover, the use of different FeNO measurement devices could also interfere with the results.…”

Section: To the Editormentioning

confidence: 99%

“…Moreover, the use of different FeNO measurement devices could also interfere with the results. To the best of our knowledge, our study [2] is the only one to compare patients' FeNO levels during acute infection and recovery in the same patients, in addition to a control group, during the COVID-19 pandemic.…”

Section: To the Editormentioning

confidence: 99%

“…Additionally, medical treatment, especially corticosteroids in moderate-severe COVID-19, has previously demonstrated a significant effect on FeNO levels. Patient medication data were collected in only 2 studies [2,3], although neither provided a statistical analysis. Some authors did report clinical characteristics that could interfere with FeNO levels (eg, age, sex, body mass index, and smoking) [10].…”

Section: To the Editormentioning

confidence: 99%

See 3 more Smart Citations

The Discrepant Role of Fractional Exhaled Nitric Oxide in SARS-CoV-2 Infection

Betancor¹,

Olaguibel²,

Sastre³

2022

J Investig Allergol Clin Immunol

Self Cite

View full text Add to dashboard Cite

Section: To the Editorcontrasting

confidence: 99%

Section: To the Editormentioning

confidence: 99%

Section: To the Editormentioning

confidence: 99%

Section: To the Editormentioning

confidence: 99%

See 2 more Smart Citations

The Discrepant Role of Fractional Exhaled Nitric Oxide in SARS-CoV-2 Infection

Betancor¹,

Olaguibel²,

Sastre³

2022

J Investig Allergol Clin Immunol

Self Cite

View full text Add to dashboard Cite

“…In any case, a small study found FeNO levels within the normal range during acute symptoms of SARS-CoV-2 infection, with some increase during the recovery phase, independently of disease severity or the patient's history of atopy. However, in patients treated with corticosteroids, a significant FeNO decrease during clinical evolution was more pronounced [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

Can FeNO be a biomarker in the post-COVID-19 patients monitoring?

Maniscalco

Ambrosino

Poto

et al. 2022

Respiratory Medicine

View full text Add to dashboard Cite

The nature of the inflammatory and fibrotic processes found in patients with post-COVID-19 syndrome makes it possible to speculate that in such patients fractional exhaled nitric oxide (FeNO) may be a useful biomarker. Consequently, we set out to verify the consistency of this hypothesis. We consecutively enrolled 68 post-COVID patients after being hospitalized for persistent clinical manifestations within 2 months from disease onset and 29 healthy volunteers as control group. None of post-COVID patients had bronchial asthma or were being treated with a corticosteroid. Only 19 out of 68 post-COVID-19 patients reported a FeNO value > 25 ppb. The mean FeNO value in post-COVID-19 patients was 18.55 ppb (95% CI: 15.50 to 21.58), while in healthy subjects it was 17.46 ppb (95% CI: 15.75 to 19.17). The mean difference was not statistically significant (P = 0.053). However, the mean FeNO value of post-COVID-19 patients was higher in men than in women (20.97 ppb; 95% CI: 16.61 to 25.33 vs 14.36 ppb; 95% CI: 11.11 to 17.61) with a difference between the two sexes that was statistically significant (P = 0.016). Mean FeNO was 14.89 ppb (95% CI: 10.90 to 18.89) in patients who had been treated with systemic corticosteroids because of their COVID-19, and 20.80 ppb (95% CI: 16.56 to 25.04) in those who had not taken them, with a difference that was statistically significant (P = 0.043). The data generated in this study suggest that measurement of FeNO is not useful as a biomarker in post-COVID-19 patient. However, this hypothesis needs solid validation with additional specifically designed studies.

show abstract

Lung function assessment in children with Long‐Covid syndrome

Sansone,

Di Filippo,

Russo

et al. 2023

Pediatric Pulmonology

View full text Add to dashboard Cite

IntroductionA significant percentage of patients who survived the Coronavirus Infection Disease 2019 (COVID‐19) showed persistent general and respiratory symptoms even months after recovery. This condition, called Post‐Acute Sequelae of COVID‐19 or Long‐Covid syndrome (LCS), has been described also in children with positive history for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Little is known about the pathophysiologic mechanisms underlying this syndrome. The aim of this study was to investigate any difference between children with LCS and asymptomatic peers with previous COVID‐19 in terms of lung function and lung ultrasound (LUS) patterns. Secondly, we tested associations between lung function abnormalities and LUS findings with Long‐Covid.MethodsWe carried out a prospective, descriptive, observational study including 58 children aged 5–17 years: 28 with LCS compared to 30 asymptomatic children with previous COVID‐19. We collected demographic data, history of asthma, allergy or smoke exposure, and acute COVID‐19 symptoms. After a median period of 4.5 months (1%–95% range 2–21) since the infection, lung function was assessed by spirometry, body plethysmography, diffusion lung capacity for carbon monoxide (DLCO). Airways inflammation was investigated by fractional exhaled nitric oxide (FeNO). LUS was performed independently by two experienced clinicians.ResultsWe found that children with LCS were older than controls (mean (SD) 12 (4.1) vs. 9.7 (2.6); p = .04). Children with LCS complained more frequently fatigue (46.4%), cough (17.9%), exercise intolerance (14.3%) and dyspnea (14.3%). Lung function was normal and similar between the two groups. The frequency of LUS abnormalities was similar between the two groups (43.3% children with LCS vs. 56.7% controls; p = .436). Children with LCS showed lower FeNO values (log difference −0.30 (CI 95% −0.50, −0.10)), but no association of LCS with a lower lung function and abnormal LUS findings was found.ConclusionsLCS seems to be more frequent in older age children. Lung functional and structural abnormalities were not different between children with LCS and asymptomatic subjects with previous COVID‐19. In addition, children with LCS showed lower FeNO values than controls, suggesting its potential role as a marker in LCS. However, further and larger studies are needed to confirm our findings.

show abstract

Evaluation of Fractional Exhaled Nitric Oxide During SARS-CoV-2 Infection

Cited by 9 publications

References 0 publications

The Discrepant Role of Fractional Exhaled Nitric Oxide in SARS-CoV-2 Infection

The Discrepant Role of Fractional Exhaled Nitric Oxide in SARS-CoV-2 Infection

Can FeNO be a biomarker in the post-COVID-19 patients monitoring?

Lung function assessment in children with Long‐Covid syndrome

Contact Info

Product

Resources

About